Related references
Note: Only part of the references are listed.Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
Jung Hwan Ji et al.
NPJ BREAST CANCER (2022)
Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
Ran Ran et al.
FRONTIERS IN ONCOLOGY (2022)
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor
Valentina Scabia et al.
NATURE COMMUNICATIONS (2022)
Characteristics and Prognosis of Estrogen Receptor Low-Positive Breast Cancer
Min Chong Kim et al.
JOURNAL OF BREAST CANCER (2022)
Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients
Jee Hyun Ahn et al.
CANCERS (2021)
Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival
Christine Dauphine et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes
Barbara J. Grabher
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY (2020)
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer
Yunhai Li et al.
JAMA NETWORK OPEN (2020)
Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV
Sung Gwe Ahn et al.
ENDOCRINE-RELATED CANCER (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies
J. Michael Dixon et al.
ADVANCES IN THERAPY (2019)
Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen
Thomas McFall et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Low Estrogen Receptor ( ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Alessandra Landmann et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
Breast cancer in young women: an overview
Zoi Anastasiadi et al.
UPDATES IN SURGERY (2017)
Prognostic and predictive value of low estrogen receptor expression in breast cancer
A. Bouchard-Fortier et al.
CURRENT ONCOLOGY (2017)
Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
A. S. Coates et al.
ANNALS OF ONCOLOGY (2015)
Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer
Soo Youn Bae et al.
BMC CANCER (2015)
A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors
Jyothi S. Prabhu et al.
JOURNAL OF CANCER (2014)
Personalized adjuvant therapies: Lessons from the past The opening address by the St. Gallen 2013 award recipient
Aron Goldhirsch
BREAST (2013)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer
Ping Tang et al.
CANCER INVESTIGATION (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors
R. Stuart-Harris et al.
BREAST (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients
Ido Wolf et al.
CANCER (2008)
Histopathologic variables predict Oncotype DX™ Recurrence Score
Melina B. Flanagan et al.
MODERN PATHOLOGY (2008)
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
Lisa K. Dunnwald et al.
BREAST CANCER RESEARCH (2007)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
